Myelodysplastic Syndromes clinical trials

Explore recruiting myelodysplastic syndromes clinical trials.

Recruiting myelodysplastic syndromes studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myelodysplastic Syndromes trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression

Germany, Italy, Denmark

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Eltrombopag for the treatment of thrombocytopenia due to low - and intermediate risk myelodysplastic syndromes.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

COMBOLA Trial: A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to ESA

France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Greece, Portugal, Romania, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)

Belgium, France, Italy, Spain, Poland, Czechia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ATOMYELO: Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk Myelodysplastic Syndromes failing Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter)

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Myelodysplastic Syndromes trials by city

Myelodysplastic Syndromes in Toronto Myelodysplastic Syndromes in Vancouver Myelodysplastic Syndromes in Montreal Myelodysplastic Syndromes in Calgary Myelodysplastic Syndromes in Edmonton Myelodysplastic Syndromes in Ottawa Myelodysplastic Syndromes in Winnipeg Myelodysplastic Syndromes in Quebec City Myelodysplastic Syndromes in Hamilton Myelodysplastic Syndromes in Kitchener Myelodysplastic Syndromes in London Myelodysplastic Syndromes in Halifax Myelodysplastic Syndromes in New York Myelodysplastic Syndromes in Los Angeles Myelodysplastic Syndromes in Chicago Myelodysplastic Syndromes in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease